TY  - GEN
N2  - For patients receiving Lu-DOTATATE therapy (four cycles every 8 weeks) for treatment of neuroendocrine tumors: does timing of laboratory assessment between treatment cycles have an impact on proportion of patients that must continue therapy at a reduced dose? And/or the proportion of patients that must postpone a subsequent infusion, or proportion of patients that must discontinue the therapy?
DO  - 10.6083/c247ds915
DO  - DOI
AB  - For patients receiving Lu-DOTATATE therapy (four cycles every 8 weeks) for treatment of neuroendocrine tumors: does timing of laboratory assessment between treatment cycles have an impact on proportion of patients that must continue therapy at a reduced dose? And/or the proportion of patients that must postpone a subsequent infusion, or proportion of patients that must discontinue the therapy?
AD  - Oregon Health and Science University
T1  - Effect of lab timing on detection of toxicities in patients Undergoing 177Lu-dotatate treatment for neuroendocrine tumors
ED  - Mittra, Erik
ED  - Mentor
DA  - 2023
AU  - Meeker, Laura
L1  - https://digitalcollections.ohsu.edu/record/10092/files/Meeker.Laura.2023.pdf
PB  - Oregon Health and Science University
PY  - 2023
ID  - 10092
L4  - https://digitalcollections.ohsu.edu/record/10092/files/Meeker.Laura.2023.pdf
KW  - Nuclear Medicine
KW  - Lutetium
KW  - Theranostic Nanomedicine
KW  - lab timing
KW  - radionuclide therapy
TI  - Effect of lab timing on detection of toxicities in patients Undergoing 177Lu-dotatate treatment for neuroendocrine tumors
Y1  - 2023
L2  - https://digitalcollections.ohsu.edu/record/10092/files/Meeker.Laura.2023.pdf
LK  - https://digitalcollections.ohsu.edu/record/10092/files/Meeker.Laura.2023.pdf
UR  - https://digitalcollections.ohsu.edu/record/10092/files/Meeker.Laura.2023.pdf
ER  -